- Obama military downsizing leaves U.S. too weak to counter global threats, panel finds
- Sen. Tom Coburn vows to slow down budget-busting bills ahead of recess
- Obama fantasizes about more executive power, signs new order on federal contractors
- Clintons call Klein, Halper, Kessler ‘a Hat Trick of despicable actors’: report
- Boehner accuses Obama of ‘legacy of lawlessness’
- Pro-marijuana group claims responsibility for Brooklyn Bridge flag swap
- Young adults shun Obamacare mostly due to cost: survey
- Stabbing attack on transgender girl, 15, was ‘bias motivated,’ police say
- LGBT adults still lean overwhelmingly toward Democratic Party
- Lawmakers rattled by Syria genocide horrors, call on Obama to act
European drugmakers hit with poor test results
Question of the Day
PARIS (AP) - Three top European pharmaceutical companies announced on Tuesday disappointing news from clinical tests on drugs they had hoped would turn out to be big sellers.
France’s Sanofi said its multiple sclerosis drug candidate teriflunomide did not achieve one of its goals in a late-stage clinical trial, while Swiss rival Novartis announced it would terminate trials of its high blood pressure treatment Rasilez for patients with diabetes and renal impairment. Britain-based AstraZeneca abandoned plans to develop a new anti-ovarian cancer drug.
Shares in the three companies underperformed European stock markets _ AstraZeneca lost 2.3 percent and Novartis 1 percent, while Sanofi gained 0.8 percent _ as investors reined in their earnings expectations.
Sanofi said teriflunomide, also known by the trade name Aubagio, worked no better than an older drug, Rebif, in preventing relapses, as the study found “no statistical superiority” between Rebif and either 7 mg or 14 mg doses of teriflunomide. Rebif is marketed by Merck KGaA of Germany.
Sanofi’s Genzyme unit enrolled 324 patients with relapsing forms of MS in a two-year study.
The study was the second of five planned efficacy studies of teriflunomide in MS. Genzyme expects to file an application for marketing approval in the European Union in the first quarter of 2012.
In Basel, Switzerland, Novartis said it was terminating a trial of its high blood pressure treatment Rasilez in high-risk patients with diabetes and renal impairment.
The drugmaker said in a statement that it terminated the study on the recommendation of the independent monitoring committee overseeing the trial. The committee found that patients were unlikely to benefit from treatment with Rasilez, and also identified higher incidences of non-fatal stroke, renal complications and other difficulties.
Rasilez, known as Tekturna in the U.S., had sales of $449 million in the first nine months of 2011 and Novartis expects sales will be negatively affected by the study results going forward. Novartis said that as a precautionary measure it will cease promotion of Rasilez/Tekturna-based products for use in combination with standard anti-hypertension treatments.
Also Tuesday, British drugmaker AstraZeneca PLC said it is abandoning plans to develop a new anti-ovarian cancer drug and that a planed antidepressant has underperformed in tests.
The British drug company said Tuesday that it would take a one-time pre-tax loss of $285 million for the failure of olaparib _ a drug that was meant to fight ovarian cancer.
It added that the underperformance of the antidepressant, known as TC-5214, in tests would cost it another $96.5 million, pre-tax.
TWT Video Picks
Both parties recognize the Democrats' scam
- Inside the Ring: Israel surprised by Hamas tunnel network
- CRUZ: A tale of two hospitals: One in Israel, one in Gaza
- Chicken pox outbreak puts illegal immigrant facility on lockdown
- Obama military strategy too weak for future security, panel reports
- Report: 40% of weapons sent to Afghanistan are unaccounted for
- Israel surprised by Hamas tunnel network
- CIA admits improperly hacking Senate computers in search of Bush-era information
- Islamic militants seize Benghazi as U.S. evacuates Libya
- 'Big Bang' star Mayim Bialik helps send bulletproof vests to IDF
- 3 African leaders cancel trip to U.S. over Ebola outbreak; Obama still plans summit
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world